TICKERNERD
Menu
OCSOCSHealthcare · Biotechnology

OCS Stock Forecast: Oculis Holding AG Price Predictions for 2026-2027

Last close, 23 Oct 2026
$7.90
−2.35% on the day

The 10 Wall Street analysts covering Oculis Holding AG hold a median 12-month price target of $40 — +403.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 32 of 100 as at 23 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$498.2M
Ticker Nerd rank
32/ 100
Median analyst target
$40
Analysts covering
10
Revenue$0.0
Operating income−$23.6M
Net income−$10.0M
Free cash flow−$20.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+8.4%
1M
−20.9%
YTD
−60.4%
1Y
−63.0%
From 52W high
−75.8%
From 52W low
+10.2%
$7
$33
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

OCS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Oculis Holding AG on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 23 Oct 2026
32/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
78
Volatility
62
Size
52
Growth
50
Accruals
41
Quality
35
Value
32
Issuance
26
Momentum
14

Revisions (78): Analysts have, on balance, been raising their forecasts.

Momentum (14): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

OCS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on OCS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50Jan 26Apr 26Jul 26Oct 26OCSHigh $44Median $40Low $20

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says10 analysts
10 Buy0 Hold0 Sell
Low $20Median $40High $44

The green dot is the last close — the median target sits +403.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
18 Sept 2026HC Wainwright & Co.MaintainsBuy$26 → $39
14 Aug 2026JP MorganMaintainsOverweight—
5 Aug 2026HC Wainwright & Co.MaintainsBuy—
3 June 2026JP MorganMaintainsOverweight—
2 June 2026BairdMaintainsOutperform—
1 June 2026GuggenheimMaintainsBuy—
1 June 2026HC Wainwright & Co.MaintainsBuy—
1 June 2026NeedhamMaintainsBuy—
1 June 2026StifelMaintainsBuy—
21 May 2026GuggenheimInitiatesBuy—
18 May 2026JP MorganMaintainsOverweight—
12 May 2026HC Wainwright & Co.MaintainsBuy—
12 May 2026NeedhamMaintainsBuy—
20 Apr 2026HC Wainwright & Co.ReiteratesBuy—
5 Mar 2026StifelMaintainsBuy—
4 Mar 2026HC Wainwright & Co.MaintainsBuy—
4 Mar 2026NeedhamMaintainsBuy—
19 Dec 2025JP MorganInitiatesOverweight—
19 Dec 2025StifelMaintainsBuy—
3 Dec 2025LifeSci CapitalInitiatesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

OCS appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.
  • The AI build-out, every Wednesday: how AI stocks did, part by part.

Free. Unsubscribe any time.

Performance

OCS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 23 Oct 2026, Oculis Holding AG returned −63.0% against +14.3% for the S&P 500, dividends included.

OCS vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120140160Jan 26Apr 26Jul 26Oct 26OCSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

OCS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
5
Analysts cutting
1
Fundamentals

Oculis Holding AG (OCS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
63.6×

Cheaper than 11% of US stocks

Price / sales
424.8×

Cheaper than 2% of US stocks

Price / book
1.9×

Cheaper than 45% of US stocks

EV / EBITDA
−3.2×

Cheaper than 77% of US stocks

Growth & margins
Revenue growth (YoY)
18.8%

Higher than 68% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
−7602.6%

Higher than 2% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−43.7%

Higher than 23% of US stocks

Return on assets
−25.0%

Higher than 16% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Oculis Holding AG (OCS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Oculis Holding AG has a market value of $498.2M and an enterprise value of $333.0M.

  • Revenue in the twelve months to 30 June 2026: $0.0. The latest quarter grew 18.8% year on year.

  • Net income over the same four quarters: −$79.2M.

  • Diluted earnings per share, trailing twelve months: $−1.39.

  • Free cash flow in the twelve months to 30 June 2026: −$65.9M.

  • Oculis Holding AG spent $0.0 on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 55.5M.

  • Trailing P/E: 63.6×; forward P/E: −4.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%.

  • Oculis Holding AG employs 60 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 25 Oct 2026

Data provided by Twelve Data

Peers

OCS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
OCSOculis Holding AG$498.2M32
INDPIndaptus Therapeutics, Inc.$485.3M30
CTMXCytomX Therapeutics, Inc.$501.5M38
CBIOCrescent Biopharma, Inc.$473.8M51
MNPRMonopar Therapeutics, Inc.$472.1M50
ENTXEntera Bio Ltd.$505.6M49
DMACDiaMedica Therapeutics, Inc.$470.2M57

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Oculis Holding AG — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest OCS news & analysis

Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor's Neuroprotective Potential in Optic Neuritis

GlobeNewsWire · 22 Oct 2026positive

Oculis reported new Phase 2 ACUITY biomarker data showing that privosegtor reduced post-onset increases in plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) compared with placebo.

Why it matters — The biomarker findings provide further support for privosegtor’s neuroprotective potential in optic neuritis, a development update relevant to OCS watchers.

Oculis Reports New Phase 2 ACUITY Biomarker Data  Further Supporting Privosegtor's Neuroprotective Potential in Optic Neuritis

GlobeNewsWire · 22 Oct 2026positive

Oculis reported new Phase 2 ACUITY biomarker data showing that privosegtor reduced post-onset increases in plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) compared with placebo.

Why it matters — The biomarker findings add data relevant to Oculis watchers assessing privosegtor’s potential in optic neuritis.

Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting

GlobeNewsWire · 20 Oct 2026positive

Oculis announced it will present late-breaking Phase 2 ACUITY biomarker analyses of privosegtor in optic neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting. The presentation highlights translational data evaluating plasma NfL and GFAP as biomarkers of neuroaxonal injury and neuroinflammation.

Why it matters — The analyses may interest OCS watchers tracking biomarker data from the Phase 2 ACUITY study of privosegtor in optic neuritis.

Oculis lýkur slembiröðun í PREDICT-1 skráningarrannsókninni á Licaminlimab við TNFR1-miðluðum augnþurrki

GlobeNewsWire · 19 Oct 2026positive

Oculis completed randomization in the PREDICT-1 registrational study of licaminlimab for TNFR1-mediated dry eye. Of 176 enrolled patients, two-thirds carry the TNFR1 genetic variant previously associated with increased clinical response in Phase 2 studies.

Why it matters — The enrollment profile is relevant to OCS watchers because it includes a majority of patients with a variant linked to greater clinical response in earlier studies.

Oculis Completes Randomization in PREDICT-1 Registrational Trial of Licaminlimab for TNFR1-Mediated Dry Eye Disease

GlobeNewsWire · 19 Oct 2026positive

Oculis said it completed randomization in the PREDICT-1 registrational trial of licaminlimab for TNFR1-mediated dry eye disease. Of 176 enrolled patients, two-thirds carry a TNFR1 genetic variant previously linked to enhanced clinical response in Phase 2 trials.

Why it matters — The update reports trial progress and the proportion of participants with the targeted genetic variant, a detail relevant to tracking the study.

FAQ

Frequently asked questions about OCS stock

What is the OCS stock price forecast for 2026-2027?

The 10 Wall Street analysts covering Oculis Holding AG have a median 12-month price target of $40, with estimates ranging from $20 to $44. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is OCS stock a buy right now?

Of the 10 analysts covering Oculis Holding AG, 10 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Oculis Holding AG 32 out of 100 across roughly 4,600 US stocks as at 23 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank OCS?

As at 23 Oct 2026, Oculis Holding AG ranks 32 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (78 of 100).

Will OCS stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +403.0% from the last close, and Ticker Nerd's factor model ranks Oculis Holding AG 32 out of 100 as at 23 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the OCS stock forecast for 2030?

No analyst covering Oculis Holding AG publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OCS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $44 over the next 12 months.

How has OCS stock performed over the past year?

Oculis Holding AG returned -63.0% over the 12 months to 23 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Oculis Holding AG do?

Oculis Holding AG is a clinical-stage biopharmaceutical company focused on developing treatments for ophthalmic, neuro-ophthalmic, and neurological diseases. Its current pipeline centers on OCS-01, a topical retinal candidate for diabetic macular edema; OCS-02, a topical biologic candidate for dry eye disease; and OCS-05, a neuroprotective candidate being studied for conditions such as acute optic neuritis and other disorders affecting vision and the nervous system.

What is the latest news on OCS?

The most recent item we track (GlobeNewsWire, 22 Oct 2026): "Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor's Neuroprotective Potential in Optic Neuritis". Oculis reported new Phase 2 ACUITY biomarker data showing that privosegtor reduced post-onset increases in plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) compared with placebo.

Company

About Oculis Holding AG.

Oculis Holding AG is a clinical-stage biopharmaceutical company focused on developing treatments for ophthalmic, neuro-ophthalmic, and neurological diseases. Its current pipeline centers on OCS-01, a topical retinal candidate for diabetic macular edema; OCS-02, a topical biologic candidate for dry eye disease; and OCS-05, a neuroprotective candidate being studied for conditions such as acute optic neuritis and other disorders affecting vision and the nervous system. The company’s work is aimed at addressing unmet medical needs in eye care through formulations designed for local delivery and patient convenience. Oculis Holding AG operates as a global life sciences business with activities in Switzerland and other international markets, serving the broader biotechnology sector through research, clinical development, and disease-specific therapeutic innovation.

CEO Dr. Riad Sherif M.B.A., M.D. · 60 employees · Switzerland · https://oculis.com